An integrated double-filtration microfluidic device for isolation, enrichment and quantification of urinary extracellular vesicles for detection of bladder cancer

Scientific Reports

Volumn 7, Issue , 2017, Pages

  Liang, Li Guo ^a,b   Kong, Meng Qi ^a,b   Zhou, Sherry ^c   Sheng, Ye Feng ^a,b   Wang, Ping ^d   Yu, Tao ^a,b   Inci, Fatih ^c   Kuo, Winston Patrick ^e,f   Li, Lan Juan ^a   Demirci, Utkan ^c,g   Wang, ShuQi ^a,b,c  

^a ZHEJIANG UNIVERSITY   (China)

^b ZHEJIANG UNIVERSITY   (China)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^e HARVARD MEDICAL SCHOOL   (United States)

^f CloudHealth Genomics Ltd   (China)

^g Stanford University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLADDER TUMOR; DEVICES; ENZYME LINKED IMMUNOSORBENT ASSAY; EXOSOME; FILTRATION; FLOW KINETICS; HUMAN; METABOLISM; MICROFLUIDICS; REPRODUCIBILITY; TUMOR CELL LINE; ULTRASTRUCTURE; URINE;

CELL LINE, TUMOR; ENZYME-LINKED IMMUNOSORBENT ASSAY; EXTRACELLULAR VESICLES; FILTRATION; HUMANS; MICROFLUIDICS; REPRODUCIBILITY OF RESULTS; RHEOLOGY; URINARY BLADDER NEOPLASMS;

EID: 85032342438     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep46224     Document Type: Article

References (33)

1. Goebell, P. J. & Knowles, M. A. Bladder cancer or bladder cancers? Genetically distinct malignant conditions of the urothelium. Urol Oncol 28, 409-428, doi: 10.1016/j.urolonc.2010.04.003 (2010).
2. Jemal, A. et al. Global Cancer Statistics. Ca - a Cancer Journal for Clinicians 61, 69-90, doi: 10.3322/caac.20107 (2011).
3. Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics, 2015. CA Cancer J Clin 65, 5-29, doi: 10.3322/caac.21254 (2015).
4. Babjuk, M. et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013. Eur Urol 64, 639-653, doi: 10.1016/j.eururo.2013.06.003 (2013).
5. Chen, W. et al. Cancer statistics in China, 2015. CA Cancer J Clin 66, 115-132, doi: 10.3322/caac.21338 (2016).
6. Kaufman, D. S., Shipley, W. U. & Feldman, A. S. Bladder cancer. Lancet 374, 239-249, doi: 10.1016/S0140-6736(09)60491-8 (2009).
7. Bethesda. SEER Cancer Stat Facts: Bladder Cancer. Cancer of the Urinary Bladder. http://seer.cancer.gov/statfacts/html/urinb.html (30/04/2016) (2016).
8. Steinberg, G. Blue Light Cystoscopy Should be Used Routinely for Bladder Cancer Detection. Journal of Urology 195, 1652-1653, doi: 10.1016/j.juro.2016.03.073 (2016).
9. Miyake, M. et al. Urinary BTA: indicator of bladder cancer or of hematuria. World Journal of Urology 30, 869-873, doi: 10.1007/s00345-012-0935-9 (2012).
10. He, H., Han, C., Hao, L. & Zang, G. ImmunoCyt test compared to cytology in the diagnosis of bladder cancer: A meta-analysis. Oncology Letters 12, 83-88, doi: 10.3892/ol.2016.4556 (2016).
11. Dimashkieh, H. et al. Evaluation of UroVysion and Cytology for Bladder Cancer Detection. Cancer Cytopathology 121, 591-597, doi: 10.1002/cncy.21327 (2013).
12. Skog, J. et al. Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat Cell Biol 10, 1470-1476, doi: 10.1038/ncb1800 (2008).
13. Zhang, Y. & Wang, X. F. A niche role for cancer exosomes in metastasis. Nat. Cell Biol. 17, 709-711 (2015).
14. Kanwar, S. S., and Dunlay, C. J., Simeone, D. M. & Nagrath, S. Microfluidic device (ExoChip) for on-chip isolation, quantification and characterization of circulating exosomes. Lab on a Chip 14, 1891-1900, doi: 10.1039/c4lc00136b (2014).
15. He, M., Crow, J., Roth, M., Zeng, Y. & Godwin, A. K. Integrated immunoisolation and protein analysis of circulating exosomes using microfluidic technology. Lab on a Chip 14, 3773-3780, doi: 10.1039/c4lc00662c (2014).
16. Wang, S. et al. Micro-a-fluidics ELISA for rapid CD4 cell count at the point-of-care. Sci Rep 4, 3796, doi: 10.1038/srep03796 (2014).
17. Wang, S. et al. Integration of cell phone imaging with microchip ELISA to detect ovarian cancer HE4 biomarker in urine at the point-of-care. Lab Chip 11, 3411-3418, doi: 10.1039/c1lc20479c (2011).
18. Wang, S. et al. Simple filter microchip for rapid separation of plasma and viruses from whole blood. International journal of nanomedicine 7, 5019-5028, doi: 10.2147/IJN.S32579 (2012).
19. Wang, S. et al. Eficient on-chip isolation of HIV subtypes. Lab Chip 12, 1508-1515, doi: 10.1039/c2lc20706k (2012).
20. Kalamvoki, M., Du, T. & Roizman, B. Cells infected with herpes simplex virus 1 export to uninfected cells exosomes containing STING, viral mRNAs, and microRNAs. Proc Natl Acad Sci USA 111, E4991-4996, doi: 10.1073/pnas.1419338111 (2014).
21. Yoshioka, Y. et al. Ultra-sensitive liquid biopsy of circulating extracellular vesicles using ExoScreen. Nat Commun 5, 3591, doi: 10.1038/ncomms4591 (2014).
22. Heinemann, M. L. et al. Benchtop isolation and characterization of functional exosomes by sequential filtration. Journal of Chromatography A 1371, 125-135, doi: 10.1016/j.chroma.2014.10.026 (2014).
23. Pisitkun, T., Shen, R. F. & Knepper, M. A. Identification and proteomic profiling of exosomes in human urine. Proceedings of the National Academy of Sciences of the United States of America 101, 13368-13373, doi: 10.1073/pnas.0403453101 (2004).
24. Hildonen, S., Skarpen, E., Halvorsen, T. G. & Reubsaet, L. Isolation and mass spectrometry analysis of urinary extraexosomal proteins. Scientific Reports 6, doi: 10.1038/srep36331 (2016).
25. Garimella, P. S. et al. Urinary uromodulin, kidney function, and cardiovascular disease in elderly adults. Kidney International 88, 1126-1134, doi: 10.1038/ki.2015.192 (2015).
26. Rampoldi, L., Scolari, F., Amoroso, A., Ghiggeri, G. & Devuyst, O. The rediscovery of uromodulin (Tamm-Horsfall protein): from tubulointerstitial nephropathy to chronic kidney disease. Kidney International 80, 338-347, doi: 10.1038/ki.2011.134 (2011).
27. Fernandez-Llama, P. et al. Tamm-Horsfall protein and urinary exosome isolation. Kidney Int 77, 736-742, doi: 10.1038/ki.2009.550 (2010).
28. Schmitz-Drager, B. J. et al. Molecular markers for bladder cancer screening, early diagnosis, and surveillance: the WHO/ICUD consensus. Urol Int 94, 1-24, doi: 10.1159/000369357 (2015).
29. Wang, S. et al. Advances in addressing technical challenges of point-of-care diagnostics in resource-limited settings. Expert review of molecular diagnostics 16, 449-459, doi: 10.1586/14737159.2016.1142877 (2016).
30. Wang, S. Q., Inci, F., De Libero, G., Singhal, A. & Demirci, U Point-of-care assays for tuberculosis: Role of nanotechnology/microfluidics. Biotechnology advances 31, 438-449, doi: 10.1016/j.biotechadv.2013.01.006 (2013).
31. Inci, F. et al. Multitarget, quantitative nanoplasmonic electrical field-enhanced resonating device (NE2RD) for diagnostics. Proc Natl Acad Sci USA 112, E4354-4363, doi: 10.1073/pnas.1510824112 (2015).
32. Inci, F. et al. Nanoplasmonic quantitative detection of intact viruses from unprocessed whole blood. ACS Nano 7, 4733-4745, doi: 10.1021/nn3036232 (2013).
33. Tokel, O. et al. Portable microfluidic integrated plasmonic platform for pathogen detection. Sci Rep 5, 9152, doi: 10.1038/srep09152 (2015).